AAMU
SUPN icon

Amundi Asset Management US’s Supernus Pharmaceuticals SUPN Stock Holding History

Amundi Asset Management US’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-5,500
Closed -$130K – 1665
2019
Q4 		$130K Hold
5,500
– – ﹤0.01% 1535
2019
Q3 		$151K Buy
+5,500
New +$163K ﹤0.01% 1514

Other funds holding SUPN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
GT
Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Amundi Asset Management US's SUPN Position: Q1 2020 in Review

Amundi Asset Management US sold out of Supernus Pharmaceuticals (SUPN) in Q1 2020, closing a stake of 5,500 shares — an estimated $130K sold.

Amundi Asset Management US first reported a position in SUPN in Q3 2019 and held it in 2 quarters. The position peaked at $151K in Q3 2019. 208 funds tracked by Wall St. Rank hold SUPN as of Q1 2020.

  • Amundi Asset Management US reported no remaining Supernus Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
  • Amundi Asset Management US sold 5,500 Supernus Pharmaceuticals shares in Q1 2020, an estimated $130K.
  • Amundi Asset Management US first reported a position in Supernus Pharmaceuticals in Q3 2019 and held it in 2 quarters.
  • Amundi Asset Management US's Supernus Pharmaceuticals position peaked at $151K in Q3 2019.
  • 208 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q1 2020.

Based on Amundi Asset Management US's 13F filing for Q1 2020, filed 15 May 2020.